Antibody Targeting to a Class I MHC-Peptide Epitope Promotes Tumor Cell Death
Authors:
Open Access
- 15 September 2006
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 177 (6) , 4187-4195
Abstract
Therapeutic mAbs that target tumor-associated Ags on the surface of malignant cells have proven to be an effective and specific option for the treatment of certain cancers. However, many of these protein markers of carcinogenesis are not expressed on the cells’ surface. Instead these tumor-associated Ags are processed into peptides that are presented at the cell surface, in the context of MHC class I molecules, where they become targets for T cells. To tap this vast source of tumor Ags, we generated a murine IgG2a mAb, 3.2G1, endowed with TCR-like binding specificity for peptide-HLA-A*0201 (HLA-A2) complex and designated this class of Ab as TCR mimics (TCRm). The 3.2G1 TCRm recognizes the GVL peptide (GVLPALPQV) from human chorionic gonadotropin β presented by the peptide-HLA-A*0201 complex. When used in immunofluorescent staining reactions using GVL peptide-loaded T2 cells, the 3.2G1 TCRm specifically stained the cells in a peptide and Ab concentration-dependent manner. Staining intensity correlated with the extent of cell lysis by complement-dependent cytotoxicity (CDC), and a peptide concentration-dependent threshold level existed for the CDC reaction. Staining of human tumor lines demonstrated that 3.2G1 TCRm was able to recognize endogenously processed peptide and that the breast cancer cell line MDA-MB-231 highly expressed the target epitope. The 3.2G1 TCRm-mediated CDC and Ab-dependent cellular cytotoxicity of a human breast carcinoma line in vitro and inhibited in vivo tumor implantation and growth in nude mice. These results provide validation for the development of novel TCRm therapeutic reagents that specifically target and kill tumors via recognition and binding to MHC-peptide epitopes.Keywords
This publication has 48 references indexed in Scilit:
- Breaking down the barriers to cancer immunotherapyNature Immunology, 2005
- Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA‐A2/Mage3 complex density using a high‐affinity TCR like monoclonal antibodyEuropean Journal of Immunology, 2005
- Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft ModelsClinical Cancer Research, 2005
- Antilymphoma Effects of Anti-HLA-DR and CD20 Monoclonal Antibodies (Lym-1 and Rituximab) on Human Lymphoma CellsCancer Biotherapy and Radiopharmaceuticals, 2004
- A listing of human tumor antigens recognized by T cells: March 2004 updateCancer Immunology, Immunotherapy, 2004
- A Novel Human Cancer Vaccine Elicits Cellular Responses to the Tumor-Associated Antigen, Human Chorionic Gonadotropin βClinical Cancer Research, 2004
- Recombinant antibodies with MHC‐restricted, peptide‐specific, T‐cell receptor‐like specificity: new tools to study antigen presentation and TCR–peptide–MHC interactionsJournal of Molecular Recognition, 2003
- Human and rodent decay‐accelerating factors (CD55) are not species restricted in their complement‐inhibiting activitiesImmunology, 2000
- Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytesTissue Antigens, 1996
- HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptidesNature, 1992